Hutchmed secured a major licensing agreement with GSK worth $110 million upfront and up to $1.295 billion in milestone payments for its cancer drug HMPL-A830 outside Greater China. The deal highlights Hutchmed's strong oncology pipeline and led to a 15% share price rise. Hutchmed will lead early global trials before GSK takes over later-stage development in western markets. Analysts see this as validation of Hutchmed's value, with upcoming FDA filings and recent clinical successes boosting outlook.
Hutchmed's shares rose 17% after signing a licensing deal with GSK worth up to $1.295 billion for its experimental cancer drug HMPL-A830. GSK gains exclusive rights outside Mainland China, Hong Kong, Macau, and Taiwan, paying $110 million upfront plu...
Moderna's stock jumped 6% even as GSK moved its mRNA-based flu vaccine into Phase III trials, signaling strong confidence in mRNA technology beyond direct competition. GSK's vaccine showed promising immune responses in mid-stage trials and targets bo...
